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SPECIAL FOCUS: STRATEGIC DIRECTIONS
IN MUSCULOSKELETAL TISSUE ENGINEERING*
CRISPR-Based Epigenome Editing of Cytokine Receptors
for the Promotion of Cell Survival and Tissue Deposition
in Inflammatory Environments
Niloofar Farhang, BS,1 Jonathan M. Brunger, PhD,2 Joshua D. Stover, MS,1 Pratiksha I. Thakore, PhD,2
Brandon Lawrence, MD,3 Farshid Guilak, PhD,4,5 Charles A. Gersbach, PhD,2
Lori A. Setton, PhD,4,5 and Robby D. Bowles, PhD1,3
Musculoskeletal diseases have been associated with inflammatory cytokine action, particularly action by TNF-a
and IL-1b. These inflammatory cytokines promote apoptosis and senescence of cells in diseased tissue and
extracellular matrix breakdown. Stem cell-based therapies are being considered for the treatment of muscu-
loskeletal diseases, but the presence of these inflammatory cytokines will have similar deleterious action on
therapeutic cells delivered to these environments. Methods that prevent inflammatory-induced apoptosis and
proinflammatory signaling, in cell and pathway-specific manners are needed. In this study we demonstrate the
use of clustered regularly interspaced short palindromic repeats (CRISPR)-based epigenome editing to alter cell
response to inflammatory environments by repressing inflammatory cytokine cell receptors, specifically TNFR1
and IL1R1. We targeted CRISPR/Cas9-based repressors to TNFR1 and IL1R1 gene regulatory elements in human
adipose-derived stem cells (hADSCs) and investigated the functional outcomes of repression of these genes.
Efficient signaling regulation was demonstrated in engineered hADSCs, as activity of the downstream tran-
scription factor NF-kB was significantly reduced or maintained at baseline levels in the presence of TNF-a or
IL-1b. Pellet culture of undifferentiated hADSCs demonstrated improved survival in engineered hADSCs treated
with TNF-a or IL-1b, while having little effect on their immunomodulatory properties. Furthermore, engineered
hADSCs demonstrated improved chondrogenic differentiation capacity in the presence of TNF-a or IL-1b, as
shown by superior production of glycosaminglycans in this inflammatory environment. Overall this work dem-
onstrates a novel method for modulating cell response to inflammatory signaling that has applications in engi-
neering cells delivered to inflammatory environments, and as a direct gene therapy to protect endogenous cells
exposed to chronic inflammation, as observed in a broad spectrum of degenerative musculoskeletal pathology.
Keywords: CRISPR, epigenome editing, adipose derived stem cells, receptor, inflammation, intervertebral disc
Introduction
Musculoskeletal diseases are a major healthcareconcern, ranking second in years lived with disabili-
ty.1 Disability due to musculoskeletal disease is increasing
and is expected to continue increasing with the rise of a
sedentary and aging population.2 Current treatments for
musculoskeletal diseases such as osteoarthritis and low back
pain (LBP) are largely palliative, and fail to restore function
or retard disease progression.3–5 The progression of multiple
musculoskeletal diseases has been associated with the action
of inflammatory cytokines that signal the breakdown of the
extracellular matrix (ECM) and promote apoptosis.6–18 One
approach for regulating this inflammation and regenerating
ECM is cell delivery to the site of disease. For example,
treatment by stem cell delivery to the intervertebral disc
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(IVD) has been investigated for degenerative disc disease
(DDD) associated with LBP.19–21 These delivered cells may
function on a short-term basis but can succumb to the delete-
rious side effects of inflammatory signaling, which includes the
induction of apoptotic pathways, protease expression, and in-
flammation maintenance.6,8,14–16,22–24 Therefore, methods that
protect therapeutically delivered cells from inflammatory en-
vironments are needed.
Here, we investigate the use of clustered regularly inter-
spaced short palindromic repeats (CRISPR)-based epigenome
editing to engineer cell response in inflammatory environ-
ments via modulation of inflammatory cytokine receptor ex-
pression. CRISPR-based epigenome editing provides highly
targeted epigenome modifications, via methylation and acet-
ylation, to regulate gene expression when targeted to regula-
tory elements and enhancers.25–30 Briefly, this system requires
the expression of a nuclease-deficient Cas9 protein (dCas9)
fused to an effector domain (transcriptional activator or re-
pressor) in combination with a single guide RNA (sgRNA).31
The sgRNA targets a specific genomic site, via a 20 base pair
sequence (gRNA) complementary to the genomic target, and
is recognized and bound by dCas9. When dCas9 is fused to
the transcription repression domain Kru¨ppel Associated
Box (KRAB) and coexpressed with a sgRNA, a complex
forms that induces site-specific H3K9 methylation to re-
press gene expression (Fig. 1A).25,29 Fusion of dCas9 to
the acetyl transferase p300 core causes site-specific histone
acetylation to upregulate genes.27 Epigenome editing sys-
tems perform highly specific and effective gene modula-
tion in mammalian cells,25,32 can be multiplexed,26,28 and
perform more robust gene downregulation than RNAi.29 In
this study, we applied this technology for use in cell-based
therapeutics and gene therapy to modulate cell response to
inflammatory signaling, with broad applications for mus-
culoskeletal pathology.
A number of inflammatory cytokines have been implicated
in musculoskeletal pathology including TNF-a, IL-1a, IL-1b,
IL-2, IL-4, IL-6, IL-8, IL-12, IL-17, and interferon-g.17,18,33–39
Two primary cytokines associated with musculoskeletal
disease, TNF- a and IL-1b, signal ECM degradation,
propagation of proinflammatory signaling, apoptosis, and
senescence.10,15,17,18,40,41 This signaling is mediated by
NF-kB, a transcription factor that induces expression of many
proinflammatory and catabolic target genes involved with
ECM breakdown and cell survival.42–44 It is hypothesized
that TNF-a and IL-1b play important roles in NF-kB-
mediated tissue breakdown, cell apoptosis, and senescence, as
NF-kB inhibition demonstrated reduced degradation in
musculoskeletal disease models.44–48 The known presence of
TNF-a and IL-1b within diseased musculoskeletal tissue
could threaten survival and anabolic activities for any stem
cell therapy for musculoskeletal pathologies.19,21,49,50
TNF-a and IL-1b exert their action on cells through their
receptors and exhibit varied responses through different
receptors. TNF-a can exhibit proinflammatory, catabolic,
and apoptotic signaling through TNFR1, but confers anti-
apoptotic effects through TNFR2.40 Furthermore, TNFR2
promotes an immunomodulatory phenotype in stem cells
within inflammatory environments.51,52 IL-1b induces pro-
inflammatory signaling via IL1R1, while IL1R2 acts as a
decoy receptor.53 Methods antagonizing inflammatory sig-
naling by direct inhibition of TNF-a and IL-1b via mono-
clonal antibodies or receptor antagonists broadly block
cytokine action, but also eliminate antiapoptotic and im-
munomodulatory signaling. In this regard, methods capable
of targeted inhibition of inflammatory cytokine/receptor
FIG. 1. (A) General mechanism
of gene repression by CRISPR-
based epigenome editing. Gene
expression occurs when chromatin
is maintained in the euchromatin
(open) configuration by acetylated
H3K9 histones. Binding of dCas9-
KRAB fusion protein via the single
guide RNA (sgRNA) and recogni-
tion of the protospacer adjacent
(PAM) sequence by dCas9 recruits
endogenous factors that replace
acetylation of H3K9 with tri-
methylation, shifting chromatin to
the heterochromatic state, therefore
silencing gene expression. (B)
Guide RNA sequences for each
gene and the control nontarget
gRNA sequence with no comple-
mentary target. (C) Lentiviral cas-
sette demonstrating components of
the epigenome editing system and
how their expression is driven.
CRISPR, clustered regularly inter-
spaced short palindromic repeats;
dCas9, nuclease-deficient Cas9
protein.














































(e.g., TNF-a/TNFR1) interactions,whichmaintain and promote
the cell-protective and immunomodulatory interactions (e.g.,
TNF-a/TNFR2), are beneficial. CRISPR epigenome editing can
be used for highly specific modulation of receptor expression,
resulting in abrogated proinflammatory and apoptotic cytokine
interactions (e.g., TNFR1 and IL1R1), while protecting anti-
inflammatory and antiapoptotic interactions (e.g., TNFR2 and
IL1R2). These systems can be used to protect endogenous cells
from apoptosis and senescence and antagonize propagation of
inflammatory signaling and/or engineer therapeutic cells de-
livered to inflammatory environments.
The objective of this study was to explore the novel ap-
plication of CRISPR-based epigenome editing to modulate
inflammatory signaling via targeted KRAB-mediated re-
pression of gene regulatory elements for TNFR1 and IL1R1.
We describe the design, construction, and screening of a
library of TNFR1 and IL1R1 epigenome targeting vectors.
Furthermore, we demonstrate how successful epigenome
editing of human adipose-derived stem cells (hADSCs), a
cell type currently used in clinical trials for musculoskeletal
disease treatment,54–56 protects them from inflammatory
signaling during culture under inflammatory challenge. This
work demonstrates that the epigenome edits promote cell
survival, ECM deposition, stem cell differentiation, and
immunomodulation under inflammatory conditions and




Experiments were conducted to build and verify lentiviral
vectors encoding TNFR1 and IL1R1 targeting CRISPR-
based transcriptional repressors, and test their ability to
engineer human cells capable of thriving in inflammatory
environments. The verified lentiviral vectors were used to
produce hADSCs with targeted repression of TNFR1 or
IL1R1 promoters, which was verified via quantitative re-
verse transcriptase–polymerase chain reaction (qRT-PCR).
Effects of this targeted repression on inflammatory signal-
ing, cell proliferation, and ECM deposition in inflammatory
conditions were tested in undifferentiated and chon-
drogenically differentiated hADSCs. Additionally, we
tested the effects of the targeted repression on the immu-
nomodulatory properties of hADSCs.
TNFR1 and IL1R1 epigenome editing construct
design and cloning
For each gene, five to six gRNAs along with a non-
targeting gRNA (Fig. 1B) were designed for screening in
HEK293T cells (described in Supplementary HEK293T
Screen: Materials and Methods and Results section; Sup-
plementary Data are available online at www.liebertpub
.com/tea). Based on screening results, four total lentiviral
CRISPR epigenome editing vectors were built, two each for
TNFR1 and IL1R1 (Supplementary Data HEK293T Screen:
Materials and Methods and Results section). Final lentiviral
constructs simultaneously expressed a single gRNA under
the control of the hU6 promoter and dCas9-KRAB-T2A-
GFP under the control of the hUbC promoter (Fig. 1C).
Epigenome editing of inflammatory cytokine receptors
in human ADSCs
Generation of engineered human ADSCs. To generate
hADSCs expressing epigenome editing tools and appropriate
controls, immortalized hADSCs (SCRC-4000, ATCC) were
separately transduced with each of the four lentiviral vectors
encoding repressors targeted to the TNFR1 and IL1R1 pro-
moters and the nontarget control vector using lentiviral
transduction methods (Supplementary Materials and Meth-
ods), and cultured in manufacturer recommended expansion
media (PCS-500-030, PCS-500-040, ATCC), until analysis.
Transduced hADSCs were analyzed for TNFR1/IL1R1 ex-
pression via qRT-PCR (Supplementary Materials and Meth-
ods; n= 3), and the vectors showing greatest TNFR1/IL1R1
downregulation were used in remaining experiments.
Inflammatory challenge: undifferentiated engineered human
ADSCs. As undifferentiated stem cell delivery is of clini-
cal interest for musculoskeletal disease,49,50,57,58 we inves-
tigated the effects of repressing the target genes in
undifferentiated hADSCs in an inflammatory environment.
NF-jB activity
To allow measurement of NF-kB activity, engineered and
control hADSCs were transduced with an NF-kB reporter
(Addgene, 49343, Supplementary Materials and Methods).
Before dosing, NF-kB reporter expressing hADSCs were
plated (5000 cells/well) in white 96-well plates in 100 mL of
expansion media and allowed to attach overnight. The fol-
lowing day, engineered hADSCs were treated with a range
(0, 0.15, and 10 ng/mL) of TNF-a or IL-1b, respectively
(n = 4). Non-transduced cells and cells transduced with the
control nontarget vector were used as controls. After 24 h of
cytokine treatment, luminescence (Bright Glo, Promega)
and cell number (Real-Time Glo, Promega) were measured.
NF-kB activity was quantified as a fold-change in lumi-
nescence relative to the untreated (0 ng/mL) cells, with NF-
kB activity normalized to cell number.
Inflammatory pellet culture challenge
Engineered and control hADSCs were maintained in pellet
culture in the presence of TNF-a or IL-1b to observe cell
proliferation and survival under inflammatory conditions
(n= 7–8/group). 250,000 cells/pellet were pelleted in 200mL
of media at 142 G for 5min. Pellets formed after 24 h and
media was replaced with media treated with 1 ng/mL of TNF-
a (nontarget and TNFR1-engineered cells) or IL-1b (non-
target and IL1R1-engineered cells). Serum-free pellet culture
media consisted of DMEM-HG with pyruvate (Thermo-
fisher), insulin (5mg/mL), transferrin (5mg/mL), selenous
acid (5 ng/mL), bovine serum albumin (1.25mg/mL),
0.17mM ascorbic acid 2-phosphate, 0.35mM proline, 0.1mm
dexamethasone, and 1% antibiotic/antimycotic (unless spec-
ified reagents were purchased from Sigma). Pellets were
cultured for 28 days with media changed every 3 days. After
28 days, pellets were either fixed for histology in 10% neutral
buffered formalin (NBF) (n= 2–3) or frozen at -80C for
quantitative biochemistry (n= 5).















































After 28 days of culture, pellets were uniformly imaged
(Pentax K5) while still in wells. Cross-sectional area of
pellets (n = 6) were calculated from images using ImageJ.59
DNA quantification
Pellet cultures (n=5/group) were analyzed for DNA content
using Hoechst dye assay.60
Histology
Pellet culture samples (n = 3/group) were fixed in 10%
NBF for 24 h, embedded in paraffin, and 5 mm sections were
cut and stained with Haematoxylin (Fisher) and Eosin
(Thermoscientific) (hematoxylin and eosin [H&E]).
Immunomodulation
To measure the effect of repression of inflammatory cy-
tokine receptors on the immunomodulatory properties of
hADSCs, we performed a peripheral blood mononuclear cell
(PBMC) proliferation assay (n = 4/group), which analyzes
immunomodulation by looking at the ability of ADSCs to in-
hibit PBMC proliferation in coculture.61–63 Mitomycin C-
treated hADSCs were plated (12,800 cells/well) in a 96-well
plate in RPMI1640 (Thermofisher) with 10% fetal bovine se-
rum (Hyclone), 100U/mL penicillin, and 0.1mg/mL strepto-
mycin (Sigma). The following day PBMCs (PCS-800-011,
ATCC) were added (102,400 cells/well), to wells with or
without hADSCs and activated with 5mg/mL phytohemagglu-
tinin (Sigma). After two days, EdU (5-ethynyl-2-deoxyuridine)
was added to 10mM at 18h before PBMC harvest. EdU in-
corporation was quantified (Click-iT EdU flow cytometry kit,
Thermofisher) in CD45 stained (560178, BD Biosciences)
PBMCs by flow cytometry. Decreases in proliferation were
calculated as the fold change in EdU and CD45-positive
PBMCs in cocultures relative to PBMCs cultured alone.
Inflammatory challenge: chondrogenically differentiated
human ADSCs. Due to interest in delivering differentiated
stem cells or to differentiate stem cells in inflammatory
environments,64–67 we investigated the effects of targeted
gene repression on chondrogenic differentiation of hADSCs
in inflammatory conditions.
Pellet culture
Engineered and control hADSCs were chondrogenically
differentiated in pellet cultures treated with TNF-a or IL-1b
to investigate effects of TNFR1/IL1R1 repression on
chondrogenesis, proliferation, and ECM deposition under
inflammatory conditions. Chondrogenic media consisted of
DMEM-HG with pyruvate (Thermofisher), 1X ITS+ pre-
mix (Corning), 0.1 mM dexamethasone, 0.35mM pro-
line, 0.17mM ascorbic acid 2-phosphate, 1% antibiotic/
antimycotic solution, and 10 ng/mL of TGFb-3 and BMP-6
(Peprotech) (unless specified all reagents were purchased
from Sigma).68–70 250,000 cells/pellet were pelleted in
200 mL of media at 142 G for 5min. After 24 h, treatment
with 1 ng/mL of TNF-a (controls and TNFR1-engineered
cells) or IL-1b (controls and IL1R1-engineered cells) began.
Pellets were cultured for 21 days with media replaced every
3 days after which pellets were either fixed in 10% NBF for
histology (n = 2–3/group) or frozen at -80C for biochemical
quantification (n= 5/group). Additionally, supernatant was
collected at each media change for biochemical quantifica-
tion (n= 7–8/group).
DNA and GAG quantification
Chondrogenic hADSC pellets (n = 5/group) and superna-
tant (n = 7–8) were analyzed for DNA content using the
Hoechst dye assay60 and/or GAG content using the modified
DMMB assay.71
Histology
Pellet culture samples (n= 3/group) were fixed in 10%
NBF for 24 h, embedded in paraffin, and 5mm sections were
cut and stained with alcian blue and nuclear fast red
(Newcomer Supply).
Statistics
All statistical analyses were performed using JMP pro
software (SAS). Quantitative RT-PCR data were analyzed
by one-way analysis of variance (ANOVA), using Dunnet’s
post hoc test (nontarget cells treated as control), using en-
gineered cell groups as the factor. PBMC proliferation assay
was analyzed by one-way ANOVA with Tukey’s post hoc
test, treating cell groups as the factor. NF-kB activity was
analyzed by two-way ANOVA with Tukey’s post hoc test,
treating cell groups and cytokine dose as factors. Pellet size,
DNA content, and GAG content data were non-normal and
analyzed by a two-way ANOVA on ranks, with Tukey’s
post hoc test, using cell groups and cytokine dose as factors.
Alpha level was set at 0.05 for all tests.
Results
Repression of inflammatory receptors in human ADSCs
Human ADSC transduction and qRT-PCR. Lentiviral
TNFR1 and IL1R1 targeting vectors were built based on
HEK293T screen (Supplementary Data HEK293T Screen:
Materials and Methods and Results section). Both TNFR1 and
IL1R1 gene expression were downregulated in hADSCs by
CRISPR-based repression, with TNFR1 repressed 90% ( p=
0.0005) by gRNA 1 and IL1R1 repressed 88% ( p< 0.0001) by
gRNA 2 relative to nontarget controls (Fig. 2A). Nontarget
controls showed no differences in receptor gene expression from
nontransduced cells ( p= 0.65 [TNFR1], p=1.00 [IL1R1]).
Inflammatory challenge: undifferentiated human ADSCs
NF-jB activity. Repression of TNFR1 expression resulted
in significant decreases in TNF-a-induced NF-kB activity at
all TNF-a doses compared to nontransduced cells ( p = 0.017
at 150 pg/mL, p < 0.0001 at 10 ng/mL, Fig. 2B). NF-kB
activity remained at untreated (0 ng/mL) cell levels at both
150 pg/mL ( p = 1.00) and 10 ng/mL ( p = 0.99) doses. Re-
pression of IL1R1 showed significantly less IL-1b-induced
NF-kB activity at 150 pg/mL of IL-1b ( p < 0.0001, Fig. 2B)
compared to nontransduced cells. NF-kB activity was
equivalent to controls at 10 ng/ml IL-1b. The nontarget
control showed no significant differences in NF-kB activity














































compared to nontransduced cells at any cytokine concen-
tration ( p = 1.00 for TNF-a dosing, p = 0.13 at 150 pg/mL
IL-1b, p = 0.55 at 10 ng/mL IL-1b).
Inflammatory cell pellet culture. Repression of TNFR1 and
IL1R1 expression demonstrated protection of undifferentiated
hADSCs from deleterious effects of TNF-a or IL-1b treat-
ment. Both TNF-a ( p= 0.024) or IL-1b ( p= 0.016) treatment
resulted in decreased cross-sectional area in nontarget control
cells, while cytokine-treated engineered cells demonstrated no
significant differences in cross-sectional area compared to
untreated (0 ng/mL) groups (TNF-a: p= 0.94, IL-1b: p= 0.90)
(Fig. 3A, B). Changes in DNA content due to TNF-a treatment
demonstrated similar effects, with significant increases in
cytokine-treated TNFR1-engineered cells compared to the
nontarget control ( p = 0.0021) (Fig. 3C). IL-1b treatment
showed similar trends for DNA content between groups,
but differences were not statistically significant ( p = 0.57)
(Fig. 3D). H&E staining of cell pellets demonstrated a de-
creased presence of cell nuclei (hematoxylin) and eosin
staining in nontarget control cytokine-treated hADSC pellets
(Fig. 3G, H) compared to all other pellet types and conditions.
Immunomodulation. Coculture of engineered hADSCs
with PBMCs demonstrated maintenance of immunomodu-
latory properties after epigenome editing (Fig. 4). Relative
to PBMCs cultured with nontransduced hADSCs, PBMCs
cultured with TNFR1-engineered hADSCs showed no sig-
nificant increase in proliferation ( p = 1.00). PBMCs cultured
with IL1R1-engineered hADSCs showed a small (11%) but
significant ( p = 0.0059) increase in PBMC proliferation
relative to nontransduced hADSCs. However, there was a
significant 43% decrease in PBMC proliferation in coculture
with IL1R1-engineered hADSCs relative to PBMCs alone
( p < 0.0001) indicating maintenance of immunomodulatory
properties after IL1R1 repression.
Inflammatory challenge: chondrogenically differentiated
human ADSCs
GAG and DNA. Chondrogenic differentiation by TGFb3
and BMP-6 was observed in both engineered and control
hADSC cells with no significant differences in GAG/pellet
observed between the untreated non-transduced control and
nontarget control ( p = 0.98), TNFR1-engineered ( p = 1.00),
or IL1R1-engineered cells ( p = 1.00) (Fig. 5). When treated
with TNF-a or IL-1b in chondrogenic media, chondrogen-
esis was inhibited in nontransduced and nontarget control
hADSCs, as noted by significant decreases in GAG content
relative to respective untreated groups (Fig. 5). These decreases
were observed for GAG/pellet (TNF-a treated: p<0.0001 (non-
transduced), p= 0.0002 (nontarget), IL-1b treated: p< 0.0001
(non-transduced), p=0.0043 (nontarget)), and GAG released
(TNF-a treated: p< 0.0001 (nontransduced), p= 0.0012 (non-
target), IL-1b treated: p<0.0001). Repression of TNFR1 re-
sulted in the protection of chondrogenesis, by returning GAG
released (p= 1.00) to untreated cell levels.GAG/pelletmeasures
were not fully returned to untreated levels in TNFR1-engineered
cells, but were significantly elevated above the TNF-a treated
nontransduced cell group (p=0.0075). IL1R1 repression re-
sulted in elevated levels of GAG released compared to both
treated controls (p= 0.0001 [nontransduced], p=0.045 [non-
target]). No differences were observed between the IL1R1-
engineered group for the GAG/pellet measure compared to
nontransduced cells treated with IL-1b (p=0.76). The trans-
ductionof epigenomeediting systemshadnoconsistent effect on
cell proliferation and no significant changes in DNA content
were observed between TNF-a or IL-1b treated and untreated
cells (TNF-a treated: p=0.51 [nontransduced], p= 1.00
[TNFR1-engineered and nontarget], IL-1b treated: p= 0.82
[nontransduced], p=1.00 [IL1R1-engineered and nontarget])
(Data not shown).
Histology. Histology was consistent with GAG/pellet
quantitative measures indicating improved pellet GAG depo-
sition in TNFR1-engineered cells, but not in IL1R1-engineered
cells (Fig. 6). As expected from quantitative data, TNFR1
repression resulted in similar alcian blue staining between
treated and untreated pellets indicating their improved
ability to differentiate and deposit ECM in the presence of
FIG. 2. Verification of lentiviral mediated gene and re-
ceptor signaling downregulation in hADSCs. Nontransduced
groups abbreviated as ‘‘No LV.’’ (A) TNFR1 and IL1R1
expression in hADSCs post-transduction of epigenome
editing system under the control of selected gRNAs (n = 3,
* = p< 0.05 [TNFR1/IL1R1-engineered vs. Nontarget con-
trol cells]). (B) Fold changes in NF-kB activity post TNF-a/
IL-1b dosing in engineered hADSCs that express the most
efficient gRNAs (TNFR1: gRNA 1, IL1R1: gRNA 2) and in
control cells (n= 4, * = p< 0.05 (cytokine-treated TNFR1/
IL1R1-engineered cells vs. cytokine-treated No LV cells),
# = p < 0.05 (TNF-a/IL-1b treated cells vs. untreated con-
trols). hADSC, human adipose-derived stem cells.














































FIG. 3. Investigation of cell survival and proliferation and ECM deposition in 3D culture by hADSCs in the presence of
cytokines. (A, B) Cross-sectional area of cell pellets in mm2, cultured with or without TNF-a/IL-1b (n= 6). (C, D) Percent
changes in DNA content relative to untreated controls (n= 4–5). (E) Representative images of untreated and TNF-a treated
pellet cultures. (F) Representative images of untreated and IL-1b treated pellet cultures. (G) H&E staining of untreated and
TNF-a treated cell pellets. (H) H&E staining of untreated and IL-1b treated cell pellets. (* = p < 0.05 compared to cytokine-
treated TNFR1/IL1R1-engineered cells, # = p < 0.05 compared to untreated control, scale bars are 50 mm). ECM, extracel-















































TNF-a. IL1R1 repression results also qualitatively matched
quantitative results, with visible decreases in GAG content
in IL1R1-engineered cells after IL-1b treatment.
Discussion
CRISPR-based epigenome editing is a highly versatile tool
with the ability to robustly upregulate and downregulate en-
dogeneous gene expression with minimal offtarget effects.30
With these features and ability to be multiplexed with or-
thogonal systems72 it provides a powerful tool for regulating
cell function. In this study we developed CRISPR-based
epigenome editing systems that modulate inflammatory sig-
naling by repressing TNFR1 and IL1R1 expression. These
editing systems have the potential to protect both endogenous
and exogenous cells within inflammatory environments by
regulating receptor expression.
Repression of inflammatory cytokine receptors TNFR1
and IL1R1 was successfully performed in multiple cell types
with repression reaching 90% in hADSCs (Fig. 2A), and
99% in HEK293T cells (Supplementary Fig. S1). The de-
gree of repression corresponded to DNase I hypersensitivity
FIG. 4. Ability of engineered hADSCS to
suppress PBMC proliferation in coculture.
Graph shows fold change in proliferation of
each coculture relative to PBMCs cultured
alone (n = 4), (* = p < 0.05 relative to PBMCs
alone, # = p < 0.05 relative to coculture with
nontransduced (No LV) hADSCs). PBMC,
peripheral blood mononuclear cell.
FIG. 5. Quantification of GAG content in pellet cultures that have undergone chondrogenic differentiation for 3 weeks
with or without the presence of TNF-a/IL-1b. Nontransduced groups abbreviated as ‘‘No LV.’’ (A, B) Amount of GAG
released into media during culture (n = 7–8). (C, D) GAG content per pellet (n = 5). (* = p < 0.05 relative to 0 ng/mL control,
# = p < 0.05 relative to cytokine-treated TNFR1/IL1R1-engineered cells).














































levels at the gRNA target site (Supplementary Fig. S1),
demonstrating the importance of targeting active promoter
regions to achieve efficient gene repression.32 It is important
to note, while trends for TNFR1 regulation were similar be-
tween HEK293T and hADSCs, IL1R1 showed opposite
trends between gRNA 1 and gRNA 2. This indicates cell type
dependence in gene repression, and it may represent varying
epigenomic regulation of IL1R1 between cell types.
We demonstrated that TNFR1 and IL1R1 regulation via
epigenome editing downregulated proinflammatory NF-kB
activity in inflammatory environments. Repression of TNFR1
signaling demonstrated a return of NF-kB activity to baseline
levels (Fig. 2B). Repression of IL1R1 led to decreased NF-kB
induction at 150pg/mL, but not at 10 ng/mL IL-1b (Fig. 2B).
Given that TNF-a and IL-1b levels are reported in the range
of 0.1–400 pg/mL (TNF-a) and 1–800pg/mL (IL-1b) in
musculoskeletal pathology,34,35,73–76 both observed responses
suggest that the therapeutic range demonstrated in this study is
consistent with musculoskeletal inflammation. Overall, this
decrease in NF-kB signaling demonstrates the ability of
CRISPR-based gene repression to downregulate this key
proinflammatory signaling mediator directly linked to mus-
culoskeletal diseases, through the propagation of inflamma-
tory signaling, apoptosis, and protease production.43–46,77
To verify that TNFR1/IL1R1 repression is protective in
inflammatory environments, we simulated hADSC delivery
to such environments by TNF-a/IL-1b treatment of en-
gineered cells in pellet culture. Cells were undifferentiated in
this experiment, as current practice delivers progenitor cells
to pathological musculoskeletal environments.50,54–56,58 Our
results demonstrated that TNFR1 and IL1R1 repression has
a protective effect in these cultures (Fig. 3). Significantly
larger cross-sectional areas in cytokine-treated TNFR1 and
IL1R1 engineered pellets, indicated protection from the
degenerative pellet phenotype. DNA content and histology
demonstrated that this was an effect of cell numbers being
maintained at untreated levels and increased ECM deposition
in engineered cell pellets. Changes in DNA content between
cytokine-treated and untreated cells demonstrated signifi-
cantly enhanced survival of TNFR1-engineered hADSCs,
when treated with TNF-a. This effect was not significant in
IL1R1-engineered hADSCs, which is consistent with the less
robust regulation of NF-kB activity observed in IL1R1-
engineered cells compared to TNFR1-engineered cells.
However, the overall increased pellet size and ECM deposi-
tion was observed in response to IL1R1 repression, indicating
protection from the degenerative phenotype.
A major concern in altering the inflammatory receptor
expression of ADSCs is the effect it may have on their
inherent immunomodulatory properties. Stem cells from
multiple sources have been shown to regulate immune cell
activity and downregulate immune cell-mediated inflamma-
tion.62,78–80 The ability for these cells to immunomodulate
has been ascribed as a possible mechanism for stem cell
action when delivered to musculoskeletal inflammatory en-
vironments.81–84 Our data demonstrate that the immuno-
modulatory capacity of hADSCs is maintained after TNFR1
or IL1R1 repression (Fig. 4). However, it has been shown that
immunomodulation is induced in stem cells via IFN-g
stimulation in combination with TNF-a/IL-1b.62,85–88
Therefore, future work considering multiplex repression of
TNFR1 and IL1R1 will need to consider its effect on stem
cell immunomodulation.
In addition to the immunomodulatory properties of
ADSCs, the ability to differentiate and promote ECM de-
position is useful for ADSC delivery to inflammatory en-
vironments. However, inflammatory conditions associated
with musculoskeletal disease inhibit chondrogenesis.89–92
Our studies investigating hADSC chondrogenesis under in-
flammatory conditions, demonstrate improved chondrogen-
esis of hADSCs with TNFR1 or IL1R1 repression in the
presence of TNF-a/IL-1b (Fig. 5). While TNFR1 repression
showed more robust protection of chondrogenesis, both gene
modifications showed improvements over nontransduced
and nontarget controls. Overall, we demonstrated beneficial
outcomes in the ability of CRISPR-based TNFR1/IL1R1
repression to allow chondrogenesis in inflammatory envi-
ronments, which has applications for stem cells delivered to
musculoskeletal inflammatory environments where differ-
entiation is desired.
FIG. 6. Alcian blue and nuclear
fast red staining of hADSC pellet
cultures that have undergone
chondrogenic differentiation for 3
weeks with or without treatment of
(A) TNF-a or (B) IL-1b (Non-
transduced groups abbreviated as
‘‘No LV,’’ scale bars are 100mm).














































It is recognized that IL1R1 regulation was less protective
than TNFR1 regulation. One possible explanation is that gene
expression only explains 30–40% of the variance in protein
abundance,93 which could indicate greater IL1R1 presence
than expected and reduced protection. Another potential
mechanism is endogenous epigenome upregulation of IL1R1
by IL-1b stimulation (as demonstrated in other cell types94–96)
overcoming our targeted epigenome modifications down-
regulating IL1R1. Finally, decreased levels of IL-1b stimu-
lation may be needed to drive inflammatory signaling,
compared to TNF-a. Future work will further investigate
these mechanisms to better understand the therapeutic po-
tential of these systems and improve our targeting of IL-1b
signaling. One potential method to obtain more robust IL1R1
signaling inhibition is gene editing by CRISPR/Cas9 systems
as their use in knocking out IL1R1 has recently shown success
in potently inhibiting IL-1a signaling.97
While hADSCs were used in this study, appropriately de-
signed CRISPR epigenome editing systems may be applied to
other stem cells of interest, as these systems have shown
efficacy in multiple cell types including embryonic and in-
duced pluripotent stem cells.98,99 Regarding clinical appli-
cation of this technology, these lentiviral systems would be
injected into a diseased joint or used to engineer therapeutic
cells ex vivo before injection into the site of interest. The
vectors in their current lentiviral form have the potential for
clinical application, as several clinical trials with lentivirus
have demonstrated promising results.100–102 If alternatives are
needed to improve the safety delivery profile, incorporation
into safe harbor sites (i.e., AAVS1, ROSA26)103 via CRISPR/
Cas9 gene editing, nonintegrating adeno-associated virus,104
or integrase deficient lentivirus105 can be considered.
Conclusion
In this study we developed tools that utilize epigenome
editing to downregulate TNFR1 and IL1R1 signaling,
pathways associated with musculoskeletal diseases. We
tested this regulation in hADSCs and demonstrated that
repression of TNFR1 and IL1R1 inhibits NF-kB activation,
promotes cell survival, protects ECM deposition, protects
differentiation, and allows maintenance of immunomodu-
latory properties in inflammatory conditions. Overall it was
demonstrated that TNFR1 and IL1R1 repression by CRISPR-
based epigenome editing provides broad application to cell
survival and function in inflammatory conditions, with po-
tential utility for treating multiple musculoskeletal conditions.
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